Nuvation Bio Inc. NUVB

Nuvation Bio Inc. es una empresa biofarmacéutica en fase clínica. La empresa se enfoca en el desarrollo de candidatos terapéuticos diferenciados y novedosos. Su cartera patentada incluye candidatos terapéuticos oncológicos mecánicamente distintos, cada uno dirigido a algunos de los tipos de cáncer difíciles de tratar. El candidato terapéutico en fase clínica de la empresa, NUV-868, es un inhibidor oral de molécula pequeña selectivo de BD2 de bromodominio y terminal extra (BET). NUV-868 inhibe la proteína BRD4, un miembro de la familia BET que regula epigenéticamente una serie de proteínas importantes que controlan el crecimiento y la diferenciación de tumores, incluidos oncogenes como c-myc. Ha diseñado NUV-868 para reducir las toxicidades terapéuticas limitantes de los inhibidores de BRD4 en desarrollo al optimizar la selectividad de BD2 versus BD1. Su plataforma de conjugado fármaco-fármaco (DDC) es un enfoque terapéutico novedoso dentro de la clase de terapias contra el cáncer de conjugados de fármacos con paralelos a los conjugados anticuerpo-fármaco (ADCs).

• The Motley Fool 29 jun

  Nuvation Bio Stock Is Up 190% Despite Recent Pressure. Should Investors Care About This $753,000 Insider Sale?

  Nuvation Bio's Chief People Officer Stacy Markel sold 125,000 shares worth $753,000 on June 23, 2026, reducing her direct holdings by 79.32%. However, the sale was executed under a pre-established trading plan adopted in December 2025, and Markel retains significant exposure through 629,810 outstanding options. Despite the stock's 190% surge over the past year and recent 40% pullback from December highs, the article suggests investors should focus more on the company's ability to convert regulatory wins into commercial growth, particularly with taletrectinib's global launch.

  

• The Motley Fool 17 jun

  Veteran Pharma VC Insider Buys 25,000 Nuvation Bio Shares as New Drug Gains Momentum

  Robert Mashal, an oncology-trained director at Nuvation Bio, purchased 25,000 shares at $4.73 per share on June 9, 2026, bringing his total indirect holdings to 225,000 shares. The purchase comes as Nuvation's first FDA-approved cancer drug, Ibtrozi, continues gaining traction with over 200 new patients per quarter since its July 2025 launch. The stock has surged 96% over the past year, and Wall Street projects revenue will nearly triple to $203 million in 2026.